Arthritis, PsoriaticPhase 2NCT01490450
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
A Phase 2 study testing BMS-945429 in people with Arthritis, Psoriatic, run by CSL Behring at 49 sites in 13 countries.
Trial summary
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic Disease modifying anti-rheumatic drugs (DMARDs). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arthritis, Psoriatic
- What is being tested?
- BMS-945429
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 165 participants
- Where
- 49 sitesin 13 countries
- Study dates
- Dec 2011to Jun 2015
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Must be on a stable background Methotrexate (MTX) therapy prior to Day1/Randomization. Subjects must have taken MTX for at least 3 months at a dose ≥ 15 mg/week to a maximum weekly dose of ≤ 25 mg/week, and be at a stable dose for 4 weeks prior to randomization (Day 1). Methotrexate dose ≥ 15 mg/week that was not efficacious and that was decreased due to toxicity as low as 10 mg/week is allowed
- Inadequate response to NSAID and/or non-biologic DMARD
- Minimum of 3 swollen and 3 tender joints
- Active psoriatic skin lesions over minimum 3% body surface area
- high sensitivity C-reactive protein (hsCRP) ≥ 0.3 mg/dL
Who cannot join
- Previously received or currently receiving concomitant biologic therapy
Trial locations and contacts
49 sites in 13 countries.
49 sites in 13 countries
United States8 sites
East Penn Rheumatology Associates, P.C.
Bethlehem, Pennsylvania, 18015
Box Arthritis And Rheumatology Of The Carolinas, Pllc
Charlotte, North Carolina, 28210
Denver Arthritis Clinic
Denver, Colorado, 80230
Arthritis Associates Of Mississippi
Jackson, Mississippi, 39202
Health Research Of Oklahoma
Oklahoma City, Oklahoma, 73103
San Diego Arthritis Medical Clinic
San Diego, California, 92108
Sarasota Arthritis Research Center
Sarasota, Florida, 34239
New England Research Associates, Llc
Trumbull, Connecticut, 06611
Poland5 sites
Local Institution
Bialystok, 15-351
Local Institution
Dąbrówka, 62-069
Local Institution
Elblag, 82-300
Local Institution
Poznan, 60773
Local Institution
Warsaw, 01-868
South Africa5 sites
Local Institution
Durban, KwaZulu-Natal, 4001
Local Institution
Panorama, Cape Town, Western Cape, 7500
Local Institution
Pinelands, Cape Town, Western Cape, 7405
Local Institution
Pretoria, Gauteng, 0083
Local Institution
Pretoria, Gauteng, 0084
Argentina4 sites
Local Institution
Capital Federal, Buenos Aires, 1015
Local Institution
Capital Federal, Buenos Aires, 1425
Local Institution
Capital Federal, Buenos Aires, 1428
Local Institution
San Miguel de Tucumán, 4000
Australia4 sites
Local Institution
Cairns, Queensland, 4870
Local Institution
Maroochydore, Queensland, 4558
Local Institution
Shenton Park, Western Australia, 6008
Local Institution
Woodville, South Australia, 5011
Canada4 sites
Local Institution
Montreal, Quebec, H2L 1S6
Centre De Rhumatologie De L Est Du Quebec
Rimouski, Quebec, G5L 8W1
Centre De Recherche Musculo-Squelettique
Trois-Rivières, Quebec, G8Z 1Y2
Manitoba Clinic
Winnipeg, Manitoba, R3A 1M3
Hungary4 sites
Local Institution
Budapest, 1023
Local Institution
Budapest, 1062
Local Institution
Debrecen, 4012
Local Institution
Veszprém, 8200
Germany3 sites
Local Institution
Bad Nauheim, 61231
Local Institution
Erlangen, 91054
Local Institution
Planegg, 82152
Mexico3 sites
Local Institution
México, Aguascalientes, 20127
Local Institution
Monterrey, Nuevo León, 64460
Local Institution
Zapopan, Jalisco, 45190
Spain3 sites
Local Institution
A Coruña, 15006
Local Institution
Barcelona, 08036
Local Institution
Seville, 41071
Czechia2 sites
Local Institution
Pardubice, 530 02
Local Institution
Prague, 128 50
Russia2 sites
Local Institution
Moscow, 115522
Local Institution
Yaroslavl, 150003
About this study
Official title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection in Adults With Active Psoriatic Arthritis
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic Disease modifying anti-rheumatic drugs (DMARDs).
- Conditions
- Arthritis, Psoriatic
- Being tested
- Placebo matching BMS-945429, BMS-945429
- Medical subject headings
- Arthritis, Psoriatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Placebo matching BMS-945429Biological
Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
BMS-945429Biological
Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
BMS-945429Biological
Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
BMS-945429Biological
Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
| Study group | Role | What they receive |
|---|---|---|
| PBO: Placebo matching BMS-945429 | Placebo comparator | Not described Receives: Biological: Placebo matching BMS-945429 |
| BMS-945429 (25mg) | Experimental | Not described Receives: Biological: BMS-945429 |
| BMS-945429 (100mg) | Experimental | Not described Receives: Biological: BMS-945429 |
| BMS-945429 (200mg) | Experimental | Not described Receives: Biological: BMS-945429 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20)
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Measured: At 16 weeks
Secondary outcomes (7)
Percent of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response Rate
To calculate the PASI score, the psoriasis plaques found on each body region are graded for their combined redness, thickness, and scaliness. The severity of the plaques in each region is graded on a 0 to 4 scale, with 0 meaning no involvement and 4 meaning severe involvement. Next, the amount of surface area on each body region that is covered by the plaques is calculated. The total surface area affected by psoriasis is graded from 0 to 6, with 0 meaning no involvement and 6 meaning greater than 90 percent of the region covered in plaques.
These grades are then fed into an equation to determine the patient's PASI score. The PASI score then is used as a clinical assessment of the patient's psoriasis involvement. A person free of psoriasis has a score of 0 and the score could be as high as 72.
PASI 75 means that the person's PASI score dropped by 75 percent as a result of the psoriasis treatment.
Measured: Week 16 and Week 24
Percent of Participants Achieving ACR50 and ACR70 Response Rate
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Measured: Week 16 and Week 24
Percent of Participants Achieving ACR20 Response Rate at Week 24
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Measured: Week 24
Percent of Participants Achieving a Health Assessment Questionnaire (HAQ) Response
For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). There are 20 questions in eight categories of functioning - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The highest component score in each category determines the score for the category, unless aids or devices are required. Dependence on equipment or physical assistance increases a lower score to the level of 2 to more accurately represent underlying disability. The eight category scores are averaged into an overall HAQ score on a scale from zero (no disability) to three (completely disabled). The scale is not truly continuous but has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 … 3).
Response is measured by a reduction of at least 0.3 unit from baseline in HAQ index.
Measured: Weeks 16 and Week 24
Mean Change From Baseline at Week 16 in Short Form (36) [SF-36] Scores
The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.
Measured: Baseline and Week 16
Mean Change From Baseline at Week 24 in SF-36 Scores
The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.
Measured: Baseline and Week 24
Number of Participants With Anti-clazakizumab Antibodies
Measured: Up to 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2011 (estimated)
- Study startDec 2011
- Primary completionJun 2013
- Study completionJun 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Arthritis, PsoriaticStudies of the same condition, open and under way.
- More trials run by CSL BehringThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 165 participants (actual)
Sponsor and investigators
- Lead sponsor
- CSL Behring
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01490450
- Sponsor's protocol ID
- IM133-004
- Other IDs
- 2011-004016-29
- Status last verified
- Oct 2021
- First submitted
- 14 Nov 2011
- Last updated
- 5 Nov 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73. doi: 10.1002/art.39700.
PubMed 27059799
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection in Adults With Active Psoriatic Arthritis
- ClinicalTrials.gov ID
- NCT01490450
- Acronym / sponsor ID
- IM133-004
- Conditions
- Arthritis, Psoriatic
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 165 participants (actual)
- Lead sponsor
- CSL BehringIndustry (pharma, biotech, devices)
- Study start
- Dec 2011
- Primary completion
- Jun 2013 (actual)
- Study completion
- Jun 2015 (actual)
- First posted
- 13 Dec 2011 (estimated)
- Results
- Posted 5 Nov 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic Disease modifying anti-rheumatic drugs (DMARDs).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| PBO: Placebo matching BMS-945429 | Placebo comparator | Biological: Placebo matching BMS-945429 |
| BMS-945429 (25mg) | Experimental | Biological: BMS-945429 |
| BMS-945429 (100mg) | Experimental | Biological: BMS-945429 |
| BMS-945429 (200mg) | Experimental | Biological: BMS-945429 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Must be on a stable background Methotrexate (MTX) therapy prior to Day1/Randomization. Subjects must have taken MTX for at least 3 months at a dose ≥ 15 mg/week to a maximum weekly dose of ≤ 25 mg/week, and be at a stable dose for 4 weeks prior to randomization (Day 1). Methotrexate dose ≥ 15 mg/week that was not efficacious and that was decreased due to toxicity as low as 10 mg/week is allowed
- Inadequate response to NSAID and/or non-biologic DMARD
- Minimum of 3 swollen and 3 tender joints
- Active psoriatic skin lesions over minimum 3% body surface area
- high sensitivity C-reactive protein (hsCRP) ≥ 0.3 mg/dL
Key exclusion criteria (1 listed)
- Previously received or currently receiving concomitant biologic therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo matching BMS-945429Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label | Biological | PBO: Placebo matching BMS-945429 |
| BMS-945429Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label | Biological | BMS-945429 (25mg) |
| BMS-945429Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label | Biological | BMS-945429 (100mg) |
| BMS-945429Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label | Biological | BMS-945429 (200mg) |
Primary outcome
Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20)
Time frame: At 16 weeks
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
7 secondary outcomes
Percent of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response Rate
Time frame: Week 16 and Week 24
Percent of Participants Achieving ACR50 and ACR70 Response Rate
Time frame: Week 16 and Week 24
Percent of Participants Achieving ACR20 Response Rate at Week 24
Time frame: Week 24
Percent of Participants Achieving a Health Assessment Questionnaire (HAQ) Response
Time frame: Weeks 16 and Week 24
Mean Change From Baseline at Week 16 in Short Form (36) [SF-36] Scores
Time frame: Baseline and Week 16
Mean Change From Baseline at Week 24 in SF-36 Scores
Time frame: Baseline and Week 24
Number of Participants With Anti-clazakizumab Antibodies
Time frame: Up to 24 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 27059799Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73. doi: 10.1002/art.39700.
Related trials for Arthritis, Psoriatic
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
Recruiting
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Rhumatoid Arthisis, Spondyloarthritis (SA)
RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Psoriatic Arthritis, Axial Spondyloarthritis
RecruitingPhase 4
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Psoriatic Arthritis (PsA)
Active, not recruitingPhase 3
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Psoriatic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol-Myers Squibb study director
Bristol-Myers Squibb
49 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing BMS-945429 in people with Arthritis, Psoriatic, run by CSL Behring at 49 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 49 sites in United States, Poland, South Africa, Argentina, Australia and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Nov 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20) (time frame: At 16 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01490450, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2021.